Search for: "Tom Lamb"
Results 821 - 840
of 1,047
Sorted by Relevance
|
Sort by Date
28 Sep 2023, 12:40 pm
Paralytic Ileus, the Slowing of Food Movement Through Digestive System, is Similar to Intestinal Obstruction (Posted by Tom Lamb at Drug Injury Watch) In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and patients that adverse reaction reports concerning ileus, a gastrointestinal disorder, have been received for semaglutide during the time since Ozempic was first approved by the FDA in 2017. [read post]
3 Dec 2012, 2:58 pm
At Least, This November 2012 Article In The New England Journal Of Medicine Makes The Point That Something Needs To Be Done Soon, Rather Than Later (Posted by Tom Lamb at DrugInjuryWatch.com) The June 2011 ruling by our United States Supreme Court in Pliva v. [read post]
24 Oct 2023, 3:20 pm
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients (Posted by Tom Lamb at Drug Injury Watch) An October 2023 medical journal article presented the results of a recent study comparing patients who used two different types of weight-loss drugs to see whether drugs containing the GLP-1 semaglutide showed Ozempic and Wegovy associated with gastroparesis, a gastrointestinal condition… [read post]
30 Apr 2025, 1:24 pm
We List Some of the Legal Liability Allegations Regarding Drug Company Actions and Failures (Posted by Tom Lamb at Drug Injury Watch) During the past several weeks, Ozempic vision loss lawsuits have been filed by patients against drug company Novo Nordisk for its alleged failure to warn about nonarteritic anterior ischemic optic neuropathy (NAION). [read post]
10 Nov 2023, 2:55 pm
A Syfovre Case of Hemorrhagic Occlusive Vasculitis-type Inflammation With Continued Blindness Is Reported (Posted by Tom Lamb at Drug Injury Watch) At the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO), various Syfovre patients eye side effects cases were discussed by William J. [read post]
18 Jul 2024, 12:53 pm
Growing Number of Pulmonary Embolism and DVT Cases Involving Semaglutide Reported by Patients (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic have been associated with an increased risk of blood clots that can lead to pulmonary embolism (sometimes called PE) and deep vein thrombosis (often called DVT). [read post]
Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?
21 Nov 2024, 12:00 pm
Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall (Posted by Tom Lamb at Drug Injury Watch) At its November 21, 2024 meeting, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will discuss whether Andexxa risks outweigh benefits. [read post]
20 Apr 2017, 12:46 pm
Focus On Medical Journal Articles About The Diagnosis And Treatment Of This Breast Implant Lymphoma Cancer Published In 2015 (Posted by Tom Lamb at DrugInjuryWatch.com) In January 2011 the U.S. [read post]
Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed
27 Dec 2023, 1:15 pm
December 2023 JAMA Ophthalmology Viewpoint Piece About Syfovre Calls for Independent and Unbiased Evaluation (Posted by Tom Lamb at Drug Injury Watch) Since the February 2023 FDA approval of Syfovre (pegcetacoplan), Apellis Pharmaceuticals has had to contend with various Syfovre safety issues related to its eye injection treatment for geographic atrophy. [read post]
26 Nov 2012, 2:35 pm
Bayer Has Settled Less Than Half The DVT And PE Blood Clot Claims Filed Or Cases Subject To Tolling Agreements (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2012 we received the Bayer Stockholders’ Newsletter which covered its third quarter financial reporting and, in particular, gave us this update about the YAZ, Yasmin, Ocella, and Gianvi products liability litigation ongoing in the U.S.: As of October 15, 2012, the number of lawsuits pending in… [read post]
5 Jul 2024, 9:30 am
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or "Eye Stroke", Can Cause Vision Loss (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent finding that the active ingredient of these three drugs semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION). [read post]
28 Jun 2024, 11:45 am
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events" (Posted by Tom Lamb at Drug Injury Watch) There seems to be some disagreement about the Syfovre safety-benefit assessment when it comes to the US FDA and its European counterpart, the European Medicines Agency (EMA). [read post]
4 Dec 2023, 2:01 pm
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss (Posted by Tom Lamb at Drug Injury Watch) We have been writing about Syfovre drug safety developments having to do with retinal vasculitis cases and other eye-related side effects since July 2023. [read post]
14 May 2024, 2:07 pm
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis (Posted by Tom Lamb at Drug Injury Watch) Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. [read post]
30 Jan 2025, 2:35 pm
While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years (Posted by Tom Lamb at Drug Injury Watch) Drug injury lawsuits that involve the contraceptive injection Depo-Provera being linked to brain tumors in some women have been filed against the responsible pharmaceutical companies over the past several months. [read post]
22 Feb 2024, 10:10 am
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes (Posted by Tom Lamb at Drug Injury Watch) Semaglutide-containing drugs that are being used for weight loss purposes include Ozempic, Rybelsus, and Wegovy. [read post]
26 Aug 2024, 9:15 am
Drug Company Apellis Failed to Warn About Retinal Vasculitis Until a November 2023 Label Change (Posted by Tom Lamb at Drug Injury Watch) We are handling Syfovre injections side effects legal compensation cases being filed for patients The basis for these product liability personal injury lawsuits is the drug company Apellis failed to warn about retinal vasculitis until a November 2023 label change. [read post]
22 Mar 2019, 11:05 am
Warning Letters Sent To Companies Mentor Worldwide And Sientra For Breast Implants Safety Monitoring Failures (Posted by Tom Lamb at DrugInjuryWatch.com) Albeit a bit off-topic for the general focus of this Drug Injury Watch blog, we have been monitoring and writing about Breast Implant Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) for the past two years. [read post]
8 Jun 2007, 5:34 am
Read the full post, as well as commentary by Tom Kane of The Legal Marketing Blog and Patrick Lamb of In Search of Perfect Client Service. [read post]
22 Mar 2013, 9:59 pm
It was likely I heard it first from either Pat Lamb or Tom Kane, both lawyer-bloggers. [read post]
